Silexion Therapeutics (SLXN) Projected to Announce Earnings on Wednesday

Posted by Brian Himes on Nov 4th, 2026

Silexion Therapeutics (NASDAQ:SLXN – Get Free Report) is anticipated to post its results before the market opens on Wednesday, November 11th. Analysts expect the company to announce earnings of ($9.10) per share for the quarter.

Silexion Therapeutics (NASDAQ:SLXN – Get Free Report) last posted its earnings results on Saturday, August 15th. The company reported ($5.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($21.20) by $16.03. On average, analysts expect Silexion Therapeutics to post ($4.70) EPS for the current fiscal year and ($1.84) EPS for the next fiscal year.

Silexion Therapeutics Price Performance

Shares of NASDAQ:SLXN opened at $0.15 on Wednesday. The firm has a fifty day moving average price of $0.28 and a two-hundred day moving average price of $6.72. Silexion Therapeutics has a one year low of $0.14 and a one year high of $32.38.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on SLXN shares. Maxim Group cut shares of Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 29th. Weiss Ratings reissued a “sell (e+)” rating on shares of Silexion Therapeutics in a research note on Friday, September 11th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Silexion Therapeutics presently has an average rating of “Hold”.

View Our Latest Stock Analysis on Silexion Therapeutics

About Silexion Therapeutics

(Get Free Report)

Silexion Therapeutics Ltd. (NASDAQ: SLXN) is an Israel-based clinical-stage biotechnology company developing RNA-based medicines for the treatment of solid tumors driven by mutations in the KRAS oncogene. The company’s technology is designed to selectively silence cancer-causing KRAS mutations while limiting exposure to healthy tissue.

Silexion’s lead program, siG12D-LODER, is an investigational RNA interference therapy targeting the KRAS G12D mutation, which is frequently found in pancreatic and other difficult-to-treat cancers.